Notification of major interest in shares

7th Oct 2010 07:00

For filings with the FSA include the annex For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Sinclair Pharma plc attached:ii

2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the Abingworth LLP

notification obligation:iii Abingworth Bioventures V LP Abingworth Bioequities Master Fund Limited

4. Full name of shareholder(s)

(if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or 6 October 2010

reached: v

6. Date on which issuer notified: 6 October 2010 7. Threshold(s) that is/are crossed or Above 3% - Abingworth Bioventures V LP reached: vi, vii Above 5% - Abingworth LLP

8. Notified details: Abingworth Bioventures V LP A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering transaction of to the triggering shares transaction if possible Number Number Number Number of voting % of voting rights xusing of of of shares rights the ISIN Shares Voting CODE Rights Direct Direct xi Indirect xii Direct Indirect Sinclair Pharma plc GB0033856740 3,569,100 3,569,100 9,214,459 9,214,459 4% 1p Ords

B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration Exercise/ Number of voting % of voting instrument date xiii Conversion Period xiv rights that may be rights acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting rights % of voting rightsfinancial date xvii Conversion instrument refers to xix, xx instrument period xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 9,214,459 4%

8. Notified details: Abingworth LLP A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering transaction of to the triggering shares transaction if possible Number Number Number Number of voting % of voting rights x using of of of shares rights the ISIN Shares Voting CODE Rights Direct Direct xi Indirect Direct Indirect xii Sinclair Pharma plc GB0033856740 5,353,650 12,880,794 5.59% 1p Ords

B: Qualifying Financial Instruments Resulting situation after the triggering transaction

Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of Exercise price Expiration Exercise/ Number of voting rights % of voting rights financial date xvii Conversion instrument refers to xix, xx instrument period xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 12,880,794 5.59%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Abingworth Bioventures V LP (which holds 9,214,459shares in the company (4%))

and Abingworth Bioequities Master Fund Limited (which holds 3,666,335 shares in the company (1.59%)) are both managed by Abingworth LLP.

Proxy Voting:

10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease

to hold:

12. Date on which proxy holder will cease to hold

voting rights: 13. Additional information: 14. Contact name: John Heard

15. Contact telephone number: 0207 534

1508

vendor

---

Related Shares:

Sinclair Pharma